2nd BD&L Summit for Life Sciences
Unlock the potential of a deal through optimizing business development activities and transactional excellence
March 10-11 | San Francisco, CA
WHAT TO EXPECT
In order to effectively evaluate any new business development opportunities and ensure that the true value of a transaction has been realized, while forecasting the probability of both development and commercial success, life science companies need to ensure the right internal experts are involved in the evaluation process. This calls for the development and continuous improvement of a formal process that will allow organizations to efficiently and effectively evaluate, negotiate, manage, and close a transaction.
The 2nd BD&L Summit serves as an open forum for cross-functional business development teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements and M&A deals.
Designed as a platform for M&A, licensing, and transaction executives to share best practices from the biotech and big pharma perspective, this conference goes one step further by providing two tracks dedicated to the following areas:
- Legal/Transactions
- Business Development
FEATURED SPEAKERS
Karah Parschauer
EVP, General Counsel
ULTRAGENYX
Linus S Lin, Ph.D.
Managing Director, Chorus
ELI LILY
Christopher Haskell, Ph.D.
Vice President, Head Open Innovation Center — North America West
BAYER
Jennifer Leeds, PH.D.
Executive Director, BD&L
NOVARTIS
Olga Kay, J.D., PH.D.
Senior IP Counsel
ROCHE MOLECULAR SOLUTIONS
Sheldon L Koenig, MBA
EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER
PORTOLA PHARMACEUTICALS
Philip Gutry
Chief Business Officer
KRONOS BIO
Jay Parish
Chief Business Officer
VIR BIOTECHNOLOGY
EVENT OVERVIEW
Given the complexities of today’s reimbursement landscape, a product’s commercial success is often the most worrying factor. In order to effectively evaluate any new business development opportunities and ensure that every potential for unlocking the value of a transaction has been realized while forecasting the probability of both development and commercial success, life science companies need to ensure the right internal experts are involved in the evaluation process. This calls for the development and continuous improvement of a formal process that will allow organizations to efficiently and effectively evaluate, negotiate, structure, and close a transaction.
The 2nd BD&L Summit for Life Sciences serves as an educational platform for cross-functional experts to share best practices for managing M&A, strategic alliances, and licensing deals, and allows teams to choose their own adventure and tailor their educational experience by attending sessions from two distinct tracks. Don’t miss this opportunity to gain a holistic view of the broader business development process and learn from your peers on how to better support your functional counterparts.
PANEL DISCUSSIONS, TWO TRACKS, AND LEADERSHIP PERSPECTIVES ON TOPICS ESSENTIAL TO YOUR SUCCESS!
- Explore best practices for companies of all sizes looking to acquire or in-license a product
- Understand how to conduct a comprehensive intellectual property due diligence investigation, and how it can alter the strategy for your deal
- Learn how to evaluate and effectively manage strategic alliances through case studies from industry leaders
- Discuss tactics to establish a unique position of leverage during negotiations with multiple parties
- Gain valuable insight into the impact company culture can have on the success of integrating the workforce post-merger or acquisition
2020 SPONSORS
